Oncological outcomes of intraperitoneal chemotherapy in advanced ovarian cancer: BRCA mutation role-Reference-Cited by-同舟云学术

Oncological outcomes of intraperitoneal chemotherapy in advanced ovarian cancer: BRCA mutation role

Published:2024-04 Issue:4 Volume:50 Page:108263
ISSN:0748-7983
Container-title:European Journal of Surgical Oncology
language:en
Short-container-title:European Journal of Surgical Oncology

Author:

Padilla-Iserte Pablo^ORCID,Iváñez Maria,Muruzabal Juan Carlos,Navarro Rafael^ORCID,Díaz-Feijoo Berta^ORCID,Iacoponi Sara^ORCID,García-Pineda Virginia,Díaz Cristina,Utrilla-Layna Jesús^ORCID,Gil-Moreno Antonio^ORCID,Serra Anna^ORCID,Gilabert-Estellés Juan,Martínez Canto Cristina^ORCID,Tejerizo Álvaro^ORCID,Lago Víctor,Cárdenas-Rebollo José Miguel^ORCID,Domingo Santiago

Publisher

Elsevier BV

Reference33 articles.

1. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease;Colombo;Ann Oncol,2019

2. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer;Alberts;N Engl J Med,1996

3. Intraperitoneal cisplatin and paclitaxel in ovarian cancer;Armstrong;N Engl J Med,2006

4. Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group

5. Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG oncology/gynecologic oncology group study;Walker;J Clin Oncol,2019